A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

MLA

Mascarenhas, John, et al. “A Phase I Study of Panobinostat (LBH589) in Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF).” British Journal of Haematology, vol. 161, no. 1, Apr. 2013, pp. 68–75. EBSCOhost, https://doi.org/10.1111/bjh.12220.

APA

Mascarenhas, J., Lu, M., Li, T., Petersen, B., Hochman, T., Najfeld, V., Goldberg, J. D., & Hoffman, R. (2013). A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). British Journal of Haematology, 161(1), 68–75. https://doi.org/10.1111/bjh.12220

Chicago

Mascarenhas, John, Min Lu, Timmy Li, Bruce Petersen, Tsivia Hochman, Vesna Najfeld, Judith D Goldberg, and Ronald Hoffman. 2013. “A Phase I Study of Panobinostat (LBH589) in Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF).” British Journal of Haematology 161 (1): 68–75. doi:10.1111/bjh.12220.